E
Elena Penza
Researcher at University of Genoa
Publications - 6
Citations - 284
Elena Penza is an academic researcher from University of Genoa. The author has contributed to research in topics: Psoriatic arthritis & Infliximab. The author has an hindex of 5, co-authored 6 publications receiving 227 citations.
Papers
More filters
Journal ArticleDOI
Infection risk associated with anti-TNF-α agents: a review
Giuseppe Murdaca,Francesca Spanò,Miriam Contatore,Andrea Guastalla,Elena Penza,Ottavia Magnani,Francesco Puppo +6 more
TL;DR: Patients who are at high risk of herpes zoster reactivation would benefit from a second vaccination in adulthood when receiving TNF-α inhibitors and the strategies for mitigating against the development of these serious adverse events are discussed.
Journal ArticleDOI
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Giuseppe Murdaca,Francesca Spanò,Miriam Contatore,Andrea Guastalla,Elena Penza,Ottavia Magnani,Francesco Puppo +6 more
TL;DR: The impact of anti-IFX and anti-ADA mAbs upon efficacy and safety ofThese biological agents decrease the possibility of achieving a minimal disease activity state, decrease drug survival, increase the need for doctors to prescribe a higher drug dosage and, finally, favor the occurrence of adverse events.
Journal ArticleDOI
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis
Giuseppe Murdaca,Simone Negrini,Ottavia Magnani,Elena Penza,Marco Pellecchio,Rossella Gulli,Paola Mandich,Francesco Puppo +7 more
TL;DR: Etanercept improve endothelial function reducing the risk of acute cardiovascular and/or cerebrovascular events and seems to favor a prompt target joint improvement without serious adverse events.
Journal ArticleDOI
Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis
Giuseppe Murdaca,Simone Negrini,Ottavia Magnani,Elena Penza,Marco Pellecchio,Francesco Puppo +5 more
TL;DR: The potential role of pharmacogenetics in predicting the response to etanercept in patients with Ps and PsA is discussed and it is shown that TNF-α −308 G/G, +489 GG and the +489 GA, TNF¬ −857C (rs1799724), TNFRSF1B 676T (rs1061622), TNFAIP3 G SNP (rs610604), FcγRIIIA-V158F
Journal ArticleDOI
Efficacy of cilostazol for the treatment of Raynaud’s phenomenon in systemic sclerosis patients
Simone Negrini,Francesca Spanò,Elena Penza,Daniela Rollando,Francesco Indiveri,Gilberto Filaci,Francesco Puppo +6 more
TL;DR: Study results indicate a potential role of cilostazol as oral maintenance therapy in SSc patients with RP, and a significant clinical improvement of RP was recorded in S sc patients undergoing cilOSTazol treatment.